Read by QxMD icon Read

Egfr slope as endpoint

Shen Li, Xiang-Rong Rao, Xi-Wen Dai, Kun Pei, Lee Wang, Bao-Min Huo, Xiu-Juan Wang, Ling-Xin Kong, Nan-Nan Zhang, Feng-Mei Lian
BACKGROUND: The high worldwide prevalence of chronic kidney disease (CKD) is a critical health problem and the development of more effective therapies is urgently needed. We conducted a randomized, double-blinded, placebo-controlled clinical trial from October 2010 to December 2012 to assess whether Fu-Zheng-Qu-Zhuo oral liquid (FZQZ) has a beneficial effect in preventing CKD progression when added to standard integrated therapies. METHODS: Patients with CKD stage 3 to 4 from 3 hospitals in Beijing, China were enrolled...
July 2017: Medicine (Baltimore)
Yu Pan, Song Jiang, Dandan Qiu, Jingsong Shi, Minlin Zhou, Yu An, Yongchun Ge, Honglang Xie, Zhihong Liu
AIMS: This study aimed to determine whether eGFRcre-cys and its slope could improve the prediction of the long-term renal outcome in patients with type 2 diabetic nephropathy (DN). METHODS: The cross-sectional and longitudinal analyses included 501 type 2DN patients from 2003 to 2009. GFR was estimated using either eGFRcre-cys or the serum creatinine-based equation (eGFRcre) or the cystatin C-based equation (eGFRcys), and was classified into 3 categories (≥90, 60-90, ≤60ml/min per 1...
November 2016: Journal of Diabetes and its Complications
Rosanna Coppo, Danilo Lofaro, Roberta R Camilla, Shubha Bellur, Daniel Cattran, H Terence Cook, Ian S D Roberts, Licia Peruzzi, Alessandro Amore, Francesco Emma, Laura Fuiano, Ulla Berg, Rezan Topaloglu, Yelda Bilginer, Loreto Gesualdo, Rosaria Polci, Malgorzata Mizerska-Wasiak, Yasar Caliskan, Sigrid Lundberg, Giovanni Cancarini, Colin Geddes, Jack Wetzels, Andrzej Wiecek, Magdalena Durlik, Stefano Cusinato, Cristiana Rollino, Milena Maggio, Manuel Praga, Hilde K Smerud, Vladimir Tesar, Dita Maixnerova, Jonathan Barratt, Teresa Papalia, Renzo Bonofiglio, Gianna Mazzucco, Costantinos Giannakakis, Magnus Soderberg, Diclehan Orhan, Anna Maria Di Palma, Jadwiga Maldyk, Yasemin Ozluk, Birgitta Sudelin, Regina Tardanico, David Kipgen, Eric Steenbergen, Henryk Karkoszka, Agnieszka Perkowska-Ptasinska, Franco Ferrario, Eduardo Gutierrez, Eva Honsova
BACKGROUND: There is a need for early identification of children with immunoglobulin A nephropathy (IgAN) at risk of progression of kidney disease. METHODS: Data on 261 young patients [age <23 years; mean follow-up of 4.9 (range 2.5-8.1) years] enrolled in VALIGA, a study designed to validate the Oxford Classification of IgAN, were assessed. Renal biopsies were scored for the presence of mesangial hypercellularity (M1), endocapillary hypercellularity (E1), segmental glomerulosclerosis (S1), tubular atrophy/interstitial fibrosis (T1-2) (MEST score) and crescents (C1)...
January 2017: Pediatric Nephrology: Journal of the International Pediatric Nephrology Association
Ki Heon Nam, Jeong Hae Kie, Mi Jung Lee, Tae-Ik Chang, Ea Wha Kang, Dong Wook Kim, Beom Jin Lim, Jung Tak Park, Young Eun Kwon, Yung Ly Kim, Kyoung Sook Park, Seong Yeong An, Hyung Jung Oh, Tae-Hyun Yoo, Shin-Wook Kang, Kyu Hun Choi, Hyeon Joo Jeong, Dae-Suk Han, Seung Hyeok Han
BACKGROUND: Proteinuria is a target for renoprotection in kidney diseases. However, optimal level of proteinuria reduction in IgA nephropathy (IgAN) is unknown. METHODS: We conducted a retrospective observational study in 500 patients with biopsy-proven IgAN. Time-averaged proteinuria (TA-P) was calculated as the mean of every 6 month period of measurements of spot urine protein-to-creatinine ratio. The study endpoints were a 50% decline in estimated glomerular filtration rate (eGFR), onset of end-stage renal disease (ESRD), and slope of eGFR...
2014: PloS One
Cristina Bucşa, Gabriel Stefan, Dorina Tacu, Ioanel Sinescu, Ruxandra Diana Sinescu, Mihai Hârza
PURPOSE: The 2012 Kidney Disease: Improving Global Outcomes (KDIGO) guidelines on chronic kidney disease (CKD) introduced risk classes for adverse outcome based on estimated glomerular filtration rate (eGFR) and albuminuria categories (low-LR, moderately-MR, high-HR, very high risk-VHR). We aimed to investigate if such risk stratification is suitable in kidney transplant (KTx) recipients. METHODS: This single-center prospective study enrolled 231 prevalent KTx recipients [36 (34-48) years, 62 % male, eGFR 53...
September 2014: International Urology and Nephrology
Tatsuo Hosoya, Kenjiro Kimura, Sadayoshi Itoh, Masaaki Inaba, Shunya Uchida, Yasuhiko Tomino, Hirofumi Makino, Seiichi Matsuo, Tetsuya Yamamoto, Iwao Ohno, Yugo Shibagaki, Satoshi Iimuro, Naohiko Imai, Masanari Kuwabara, Hiroshi Hayakawa
BACKGROUND: Hyperuricemia is a risk factor for the onset of chronic kidney disease (CKD) and is significantly associated with the progression of CKD. However, there is no sufficient evidence by interventional research supporting a cause-effect relationship. Hyperuricemic patients without gouty arthritis, whose serum urate (SUA) concentration is ≥8.0 mg/dL and who have a complication, are treated by pharmacotherapy in addition to lifestyle guidance. Nevertheless, there is no evidence that rationalizes pharmacotherapy for patients with hyperuricemia who have no complication and whose SUA concentration is below 9...
January 16, 2014: Trials
Szu-Chia Chen, Jer-Ming Chang, Yi-Chun Tsai, Ho-Ming Su, Hung-Chun Chen
Heart failure and increased arterial stiffness are associated with declining renal function. This longitudinal study was designed to assess whether the combination of brachial-ankle pulse wave velocity (baPWV) and the ratio of brachial pre-ejection period (bPEP) to brachial ejection time (bET) was independently associated with renal outcomes in patients with chronic kidney disease (CKD), stages 3-5. The baPWV and bPEP/bET values were measured using an ankle-brachial index (ABI)-form device in 186 patients who were classified into 4 groups according to the baPWV and bPEP/bET median values...
December 2012: Hypertension Research: Official Journal of the Japanese Society of Hypertension
Hui Gao, Tao Wang, Ren-Huan Yu
OBJECTIVE: To assess the therapeutic effects of Chinese medicine (CM) treatment mainly by Modified Shenqi Dihuang Decoction (MSDD) in delaying the progress of chronic renal failure (CRF). METHODS: A prospective cohort method was employed. CRF patients with serum creatinine (SCr) ranging between 133 and 442 micromol/L were recruited. Those in the CM treatment group (61 cases) were treated with MSDD as well as basic treatment of Western medicine, while those in the control group (57 cases) were treated with basic treatment of Western medicine alone...
January 2012: Chinese Journal of Integrated Traditional and Western Medicine
Glenn Liu, Yu-Hui Chen, Jill Kolesar, Wei Huang, Robert Dipaola, Michael Pins, Michael Carducci, Mark Stein, Glenn J Bubley, George Wilding
PURPOSE: Activation of the epidermal growth factor pathway is important in prostate cancer development and the transcription of androgen receptor regulated genes. This study evaluated the potential activity of lapatinib in men with biochemically-relapsed androgen-dependent (stage D0) prostate cancer. PATIENTS AND METHODS: Patients with a rising PSA after primary therapy for prostate cancer were enrolled. A PSA doubling time (PSADT) <12 months was required. Lapatinib was administered at 1,500 mg orally daily...
February 2013: Urologic Oncology
Szu-Chia Chen, Jer-Ming Chang, Wan-Chun Liu, Yi-Chun Tsai, Jer-Chia Tsai, Po-Chao Hsu, Tsung-Hsien Lin, Ming-Yen Lin, Ho-Ming Su, Shang-Jyh Hwang, Hung-Chun Chen
BACKGROUND AND OBJECTIVES: Increased arterial stiffness was reported to be associated with decreased estimated GFR (eGFR). Previous studies suggested that arterial stiffness might play a role in renal function progression in patients with chronic kidney disease (CKD). The aim of this study was to investigate whether there was an independent association between brachial-ankle pulse wave velocity (baPWV), a marker of arterial stiffness, and renal function progression in CKD patients. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: This longitudinal study enrolled 145 patients with CKD stages 3 to 5...
April 2011: Clinical Journal of the American Society of Nephrology: CJASN
Frank A Holtkamp, Dick de Zeeuw, Merlin C Thomas, Mark E Cooper, Pieter A de Graeff, Hans J L Hillege, Hans-Henrik Parving, Barry M Brenner, Shahnaz Shahinfar, Hiddo J Lambers Heerspink
Intervention in the renin-angiotensin-aldosterone-system (RAAS) is associated with slowing the progressive loss of renal function. During initiation of therapy, however, there may be an acute fall in glomerular filtration rate (GFR). We tested whether this initial fall in GFR reflects a renal hemodynamic effect and whether this might result in a slower decline in long-term renal function. We performed a post hoc analysis of the Reduction of Endpoints in Non-Insulin-Dependent Diabetes Mellitus with the Angiotensin II Antagonist Losartan (RENAAL) trial...
August 2011: Kidney International
Uwe Schwarzwälder, Michael Hauk, Thomas Zeller
BACKGROUND: Prospective, international, multi-centre, randomised (1:1) trial to evaluate the clinical impact of percutaneous transluminal renal artery stenting (PTRAS) on the impaired renal function measured by the estimated glomerular filtration rate (eGFR) in patients with haemodynamically significant atherosclerotic renal artery stenosis. METHODS: Patients will be randomised to receive either PTRAS using the Dynamic Renal Stent system plus best medical treatment or best medical treatment...
July 27, 2009: Trials
Linda F Fried, William Duckworth, Jane Hongyuan Zhang, Theresa O'Connor, Mary Brophy, Nicholas Emanuele, Grant D Huang, Peter A McCullough, Paul M Palevsky, Stephen Seliger, Stuart R Warren, Peter Peduzzi
Both angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) can slow the progression of diabetic nephropathy. Even with ACEI or ARB treatment, the proportion of patients who progress to end-stage renal disease (ESRD) remains high. Interventions that achieve more complete blockade of the renin-angiotensin system, such as combination ACEI and ARB, might be beneficial. This approach may decrease progression of nondiabetic kidney disease. In diabetic nephropathy, combination therapy decreases proteinuria, but its effect in slowing progression is unknown...
February 2009: Clinical Journal of the American Society of Nephrology: CJASN
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"